The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis
- PMID: 20182803
- DOI: 10.1007/s11033-010-0004-7
The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis
Abstract
The vacuolar ATPase (V-ATPase) is a multisubunit enzyme that couples ATP hydrolysis to proton pumping across membranes. Recently, there is increasing evidence that V-ATPase may contribute to the pathogenesis of bone resorption disorders due to it is predominantly expressed in osteoclasts also function in bone resorption making it a good candidate in a therapeutic target for osteoporosis. Osteoclasts are capable of generating an acidic microenvironment necessary for bone resorption by utilizing V-ATPases to pump protons into the resorption lacuna. In addition, it has been shown that therapeutic interventions have been proposed that specifically target inhibition of the osteoclast proton pump. Modulation of osteoclastic V-ATPase activity has been considered to be a suitable therapy for the treatment of osteoporosis. All theses findings suggest that V-ATPase have important biological effects in bone resorption that might be a promising therapeutic target for osteoporosis. In this review, we will briefly discuss the biological features of osteoporosis and summarize recent advances on the role of V-ATPase in the pathogenesis and treatment of osteoporosis.
Similar articles
-
Disruption of the V-ATPase functionality as a way to uncouple bone formation and resorption - a novel target for treatment of osteoporosis.Curr Protein Pept Sci. 2012 Mar;13(2):141-51. doi: 10.2174/138920312800493133. Curr Protein Pept Sci. 2012. PMID: 22044152 Review.
-
V-ATPases in osteoclasts: structure, function and potential inhibitors of bone resorption.Int J Biochem Cell Biol. 2012 Sep;44(9):1422-35. doi: 10.1016/j.biocel.2012.05.014. Epub 2012 May 29. Int J Biochem Cell Biol. 2012. PMID: 22652318 Review.
-
Selective inhibition of osteoclast vacuolar H(+)-ATPase.Curr Pharm Des. 2002;8(23):2033-48. doi: 10.2174/1381612023393369. Curr Pharm Des. 2002. PMID: 12171517 Review.
-
V-ATPases and osteoclasts: ambiguous future of V-ATPases inhibitors in osteoporosis.Theranostics. 2018 Oct 26;8(19):5379-5399. doi: 10.7150/thno.28391. eCollection 2018. Theranostics. 2018. PMID: 30555553 Free PMC article. Review.
-
Structure and function of V-ATPases in osteoclasts: potential therapeutic targets for the treatment of osteolysis.Histol Histopathol. 2007 Apr;22(4):443-54. doi: 10.14670/HH-22.443. Histol Histopathol. 2007. PMID: 17290355 Review.
Cited by
-
Bovine parathyroid hormone enhances osteoclast bone resorption by modulating V-ATPase through PTH1R.Int J Mol Med. 2016 Feb;37(2):284-92. doi: 10.3892/ijmm.2015.2423. Epub 2015 Dec 7. Int J Mol Med. 2016. PMID: 26647715 Free PMC article.
-
Autosomal recessive osteopetrosis: report of 41 novel mutations in the TCIRG1 gene and diagnostic implications.Osteoporos Int. 2012 Nov;23(11):2713-8. doi: 10.1007/s00198-011-1878-5. Epub 2012 Jan 10. Osteoporos Int. 2012. PMID: 22231430
-
Native homing endonucleases can target conserved genes in humans and in animal models.Nucleic Acids Res. 2011 Aug;39(15):6646-59. doi: 10.1093/nar/gkr242. Epub 2011 Apr 27. Nucleic Acids Res. 2011. PMID: 21525128 Free PMC article.
-
Lamins and bone disorders: current understanding and perspectives.Oncotarget. 2018 Apr 27;9(32):22817-22831. doi: 10.18632/oncotarget.25071. eCollection 2018 Apr 27. Oncotarget. 2018. PMID: 29854317 Free PMC article. Review.
-
Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.Mol Med. 2022 Feb 19;28(1):21. doi: 10.1186/s10020-022-00448-x. Mol Med. 2022. PMID: 35183103 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical